Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
However, in 2016, Novo Nordisk halted the development of their basal oral insulin tablet.
Read More »ADA: Basal Oral Insulin Tablet Reduces Fasting Blood Glucose and HbA1c Levels Similar to Insulin Glargine in Patients with Type 2
ADA: Effects of REMD-477, a Glucagon-Blocking Drug, in Patients with Type 1 Diabetes
Results presented in the ADA 77th Scientific Sessions suggests the use of an investigational glucagon-blocking agent can improve glycemic levels and reduce insulin requirements.
Read More »ADA: Degludec Deemed Non-Inferior to Glargine Regarding Cardiovascular Safety in High Risk Patients with Type 2
The DEVOTE trial compared cardiovascular safety in two basal insulins; insulin degludec was found to have additional benefits.
Read More »Degludec Versus Glargine: Evaluating Differences in Glycemic Variabilities and Patient Satisfaction
One long-acting insulin may be better at controlling glycemic variations.
Read More »Insulin & Vascular Function Part 6
In this week's Homerun Slides, beta cell failure in type 2 diabetes mellitus and the concept of glucotoxicity.
Read More »Insulin & Vascular Function Part 5
n this week's Homerun Slides, finding the common ground between - and possible path to treatment of - hyperglycemia and the causes of vascular disease.
Read More »Insulin & Vascular Function Part 3
In this week's Homerun Slides, a continued explanation of insulin resistance and its causes, as well as its impact on hyperinsulinemia.
Read More »Insulin & Vascular Function Part 2
In this week's Homerun Slides, the effects of hyperinsulinism.
Read More »Did You Know: Safety Concerns for Diabetes Medications
When it comes to antidiabetic therapies, professionals should be aware of safety concerns with concentrated insulin formulations, metformin and renal function, and SGLT-2 inhibitors and DKA. See the breakdown of these safety issues by Tom Palma, RPh, MS, BCPS, and Greg Wiggers, PharmD, PhD, plus exclusive commentary by DIC Advisory Board member Dr. George Bakris.
Read More »Assessing and Changing Insulin Onset
Female, 26 years of age, type 1 diabetes for 15 years, well-educated, uses insulin pump. Recent A1C 7.6%; has been rising from 6 to 6.5. Thinks her mealtime insulin is not working fast enough. She does bolus about 20 minutes before eating. Assessed pump, CGM, food intake and activity. Her report seemed to be the case.
Read More »